LDL-C management: Should it begin in the cath lab?

Gilles Montalescot is Professor of Cardiology at the Pitié Salpêtrière Hospital in Paris, France, where he heads the Department of Cardiology at the Institute of Cardiology. He is a practicing Interventional Cardiologist and has extensive experience in basic and clinical research. He has been the director of the INSERM research Unit UMRS_1166 on Thrombosis for 10 years.

Dr Montalescot has been an investigator for many of the new drugs developed in the past twenty years as well as for many of the new interventional technologies. Dr Montalescot is a senior scientist and has been the lead investigator of many national or international randomized trials including ADMIRAL, ARMADA, ALBION, STEEPLE, ARCHIPELAGO, ABOARD, ACAPULCO, ATOLL, ARCTIC, ANTARCTIC, ACCOAST, ATLANTIC, AEGEAN, AMERICA, ALBATROS, and the ongoing ATLANTIS, ALPHEUS, ARAMIS, ADRIFT trials.

Dr Montalescot is the Chairman of the ACTION study group, an Academic Research Organization based at Pitié Salpêtrière Hospital in Paris. He has served on several task force committees on antithrombotic drugs and acute coronary syndromes and is the current Chairman of the Stable Coronary Artery disease guidelines of the European Society of Cardiology.

Dr Montalescot has received several awards in his country including the J. Valade Prize from the Fondation de France and the J.Escalle award from the National Academy of Medicine. He is a member of several editorial boards and has published over 600 peer reviewed original articles in journals such as the NEJM, JAMA, Lancet. Internationally, Dr Montalescot has also been an invited speaker at plenary sessions of major congresses such as the European Society of Cardiology, the American College of Cardiology ,and the American Heart Association.

Dr. Rogers brings a wealth of experience to HeartFlow, where he serves as the Executive Vice President and Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA. He received his A.B. from Harvard College and his M.D. from Harvard Medical School.